In lung cancer, co-occurring genomic alterations, particularly in TP53 and LKB1 (also known as STK11), have been proven to be core determinants of the molecular and clinical heterogeneity of oncogene-driven subgroups [34]. This evidence concerns the gene STK11 and lung carcinoma.